"Designing Growth Strategies is in our DNA"
The World Health Organization (WHO) has recently declared COVID-19 as a health emergency. Rapidly increasing cases of COVID-19 has put a tremendous pressure on the healthcare system to develop effective and safe treatment to combat the deadly virus. There were around 2 million cases and around 127,000 deaths attributed to COVID-19 as of 15th April based on the data published by the Johns Hopkins University & Medicine’s Coronavirus Resource Center. Perpetual efforts being taken by pharmaceutical companies, government agencies and other organisations to find a cure for this deadly outbreak is evident from the announcements of the potential treatments, partnerships and collaborations happening on a daily basis.
Some of the important announcements are as follows:
Most of the research activities are being funded by government agencies and charities. Support from the government agencies and the regulatory bodies in terms of fast tracking the approval process and simplifying enrolment of participants is expected to boost the research activities in COVID 19 treatment development.
Major pharmaceutical companies have also entered the race to develop a treatment for coronavirus and several companies have started evaluating the efficacy of their drugs, which are used in treatment of other conditions, as a potential cure for COVID-19.
In recent findings, hydroxychloroquine was found to be effective against coronavirus. India is the largest supplier of the hydroxychloroquine, which fulfils 70% of the global demand, has removed ban on export of the medicine to other countries. The rapid spread of the outbreak, rising death toll, and significant impact on the economy due to the lockdown are propelling research activities and increasing the number of molecules that are being tested clinically.
At present, there is no approved therapy for the treatment or prevention of the COVID-19. However, more than 300 active clinical trials are being conducted all over the world.
These trials can be broadly categorized as below:
The pharmaceutical interventions found for COVID-19 treatment include human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, oseltamivir, favipiravir, carrimycin, methylprednisolone, bevacizumab, thalidomide, vitamin C, pirfenidone, bromhexine, fingolimod, danoprevir, ritonavir, darunavir, cobicistat, lopinavir, xiyanping, and traditional Chinese medicines (TCM).
To know how our report can help streamline your business, Speak to Analyst
At present, around phase 2 and phase 3 candidates account for 72% of the total studies being conducted and pharmaceutical companies, government organizations, and other drug manufacturers have sponsored majority of the studies.
Estimated Completion Date
Hydroxychloroquine and Dietary Supplement: Vitamin C
Providence Health & Services
Nitazoxanide 500 MG and Hydroxychloroquine
Hugo Mendieta Zeron
December 30, 2020
The report on ‘COVID-19 Treatment – Pipeline Review, 2020’ provides a comprehensive overview of the drug molecules that are in the R&D pipeline by molecule, recruitment stage, phases, study type, gender, and other factors such as age group and sponsor. The report also provides a thorough analysis of the candidates by clinical trial phases, company, and details such as clinical trial stage, molecule type, mechanism of action, number of recruitment, location, institution and sponsor for every product in the pipeline.
Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview, industry developments, comparison of COVID 19 pandemic with previous pandemics such as SARS, Influenza, and MERS, and steps taken by the government/industry for the development of drugs against COVID-19. The report will also throw light on some of the market indicators such as aging population and prevalence of chronic diseases by country/region.
The report will also offer insights on drug candidates that have a higher chance of success based on various factors such as the stage of development, type and players involved. Moreover, the report will additionally provide a comprehensive analysis of potential addressable market of these drug candidates in terms of value and volume.
The report on ‘COVID-19 Treatment – Pipeline Review, 2020’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry